Physician profile
Ajit Maniam
NPI 1205802618
$9,957.51
in general payments reported to CMS, 2019-2025
72 companies · $42.23 in 2025
The $42.23 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $124 · 2021: $1,216 · 2022: $2,422 · 2023: $2,640 · 2024: $2,954 · 2025: $42.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,637.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $783.42 | 2019-2024 | Imbruvica, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $756.00 | 2021-2024 | Calquence, Lynparza, Tagrisso |
| Incyte Corporation | $729.81 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $677.09 | 2021-2024 | Reblozyl, Pomalyst |
| Eisai INC. | $483.29 | 2019-2024 | |
| Pfizer INC. | $467.59 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $466.10 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Gilead Sciences, INC. | $445.36 | 2019-2024 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $309.23 | 2022-2024 | |
| Genentech USA, INC. | $250.20 | 2019-2023 | Tecentriq, Perjeta, Phesgo |
| Astellas Pharma US INC | $234.97 | 2020-2024 | Padcev, Xospata, Xtandi |
| Daiichi Sankyo INC. | $230.15 | 2021-2024 | Enhertu |
| Amgen INC. | $215.39 | 2021-2023 | Lumakras |
| Puma Biotechnology, INC. | $212.16 | 2019-2024 | Nerlynx |
| Novartis Pharmaceuticals Corporation | $189.92 | 2022-2025 |
Show all 65 companies
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajit Maniam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.